ADAR1 Capital Management Sells Shares in Keros Therapeutics

ADAR1 Capital Management, LLC, along with its affiliates, has entered into a stock purchase agreement with Keros Therapeutics, Inc. to sell a total of 5,389,264 shares of common stock at $17.75 per share, amounting to an aggregate price of $95,659,436. The agreement includes standstill provisions that restrict the ADAR1 Parties from acquiring more than 4.9% of the outstanding shares of common stock during the standstill period, which ends after the 2028 Annual Meeting of Stockholders. The transaction is part of Keros Therapeutics' Capital Return Program, aimed at returning $375 million in excess capital to its stockholders. The filing also includes details of the representations, warranties, and covenants made by both parties.